Company: REVB
Filing Date: 2025-05-20
Form Type: S-1
Source: 0001213900-25-045828
Chunk: 61

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-20
Form: S-1
Chunk 61
---
 willfully obstructing a criminal investigation     
 of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or      
 making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, 
 items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have  
 actual knowledge of the statute or specific intent to violate it in order to have committed a violation.                                  |

| ● | Patient data privacy and security regulation, including,                                                                                         
 in the United States, HIPAA, as amended by the Health Information Technology for Clinical Health Act of 2009 (“HITECH”),                         
 and their respective implementing regulations, which impose specified requirements on “covered entities,” including healthcare                   
 providers, health plans, and healthcare clearinghouses, as well as their respective “business associates” that perform services                  
 for them that involve the use, or disclosure of, individually identifiable health information relating to the privacy, security and transmission 
 of individually identifiable health information.                                                                                                 |

| ● | The federal transparency requirements under the Physician                                                                                     
 Payments Sunshine Act, enacted as part of the Affordable Care Act, that require applicable manufacturers of covered drugs, devices, biologics 
 and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with                
 specific exceptions, to track and annually report to CMS payments and other transfers of value provided to physicians and teaching hospitals  
 and certain ownership and investment interests held by physicians or their immediate family members in the applicable manufacturer, and       
 disclosure of such information will be made by CMS on a publicly available website.                                                           |

| ● | Analogous state, local or foreign laws, such as state anti-kickback                                                                     
 and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state   
 and local marketing and/or transparency laws applicable to manufacturers that may be broader in scope than the federal requirements;    
 state laws that require biopharmaceutical companies to comply with the biopharmaceutical industry’s voluntary compliance guidelines     
 and the relevant compliance guidance promulgated by the federal government; state and local laws that require licensure or registration 
 by sales and marketing agents of a pharmaceutical company; state laws that require disclosure of information related to drug pricing;   
 and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from